local_hospital

A.O. Busto Arsizio P.O. Saronno

Address
Piazzale Borella 1, 21047 Saronno, Italy

A.O. Busto Arsizio P.O. Saronno - Oncology Research Center

A.O. Busto Arsizio P.O. Saronno is a specialized oncology research center dedicated to advancing cancer treatment through innovative clinical trials. The center demonstrates particular expertise in addressing complex therapeutic challenges in breast cancer and non-small-cell lung cancer, with a focus on optimizing treatment sequencing and combination therapies for improved patient outcomes.

  • Adjuvant therapy optimization in endocrine-responsive early breast cancer
  • Advanced non-small-cell lung cancer treatment strategies following chemo-immunotherapy
  • Novel combination therapies integrating chemotherapy with immunotherapy and targeted agents

The research center's clinical trial portfolio reflects a commitment to addressing critical questions in treatment timing and sequencing, particularly examining concurrent versus sequential administration of multiple therapeutic modalities. Their work encompasses both early-stage and metastatic disease settings, contributing valuable evidence to guide personalized oncology treatment approaches for post-menopausal breast cancer patients and advanced lung cancer populations who have progressed on first-line therapies.

Site Overview

assignment
2
connected trials
corporate_fare
2
sponsors
science
14
IMPs

Activity Indicator

Last 6 months

0
Trials started
0
Trials started 6–12 months ago
2
Total trials linked
Moderately Active
trending_flatStable0%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
1
Sponsors (total)
2
Active sponsors
1

Sponsor Network

Top 1 by active trials.

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

No repeated partnerships found.

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 566 other sites in Italy

description
Trial volume
2
Outperforms 36% of sites
public
Therapeutic diversity
1areas
Outperforms 1% of sites
groups
Sponsor diversity
2sponsors
Outperforms 37% of sites

Therapeutic Area Benchmark — Italy

Select a therapeutic area to compare against other sites in Italy.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Italy

Market Share

Country: Italy

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in A.O. Busto Arsizio P.O. Saronno

lock Showing 1 of 2 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
Phase II Randomized Trial of Tedopi with Docetaxel or Nivolumab in Metastatic NSCLC Post-ChemoimmunotherapyFondazione Ricerca TraslazionalePhase IIRecruitingFeb 2025

IMP list

lock Showing 1 of 14 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Anastrozole1Unknown2025-02-032025-02-03

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.